PAHC Quote, Financials, Valuation and Earnings

Boston Scientific Corp. has a net margin of 7.29% compared to Phibro Animal Health Corp.'s net margin of 14.91%. Phibro Animal Health Corp.'s return on equity of 24.77% beat Boston Scientific Corp.'s return on equity of 12.46%.

Phibro Animal Health Corp. has a consensus price target of $43.00, signalling upside risk potential of 3.89%. On the other hand Boston Scientific Corp. has an analysts' consensus of $126.48 which suggests that it could grow by 28.32%. Given that Boston Scientific Corp. has higher upside potential than Phibro Animal Health Corp., analysts believe Boston Scientific Corp. is more attractive than Phibro Animal Health Corp..

Phibro Animal Health Corp. has a beta of 0.771, which suggesting that the stock is 22.868% less volatile than S&P 500. In comparison Boston Scientific Corp. has a beta of 0.673, suggesting its less volatile than the S&P 500 by 32.691%.

Phibro Animal Health Corp. has a quarterly dividend of $0.12 per share corresponding to a yield of 1.16%. Boston Scientific Corp. offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Phibro Animal Health Corp. pays 40.46% of its earnings as a dividend. Boston Scientific Corp. pays out -- of its earnings as a dividend. Phibro Animal Health Corp.'s payout ratio is sufficient to cover dividend payouts with earnings for the foreseeable future.

Phibro Animal Health Corp. quarterly revenues are $363.9M, which are smaller than Boston Scientific Corp. quarterly revenues of $5.1B. Phibro Animal Health Corp.'s net income of $26.5M is lower than Boston Scientific Corp.'s net income of $755M. Notably, Phibro Animal Health Corp.'s price-to-earnings ratio is 24.88x while Boston Scientific Corp.'s PE ratio is 52.72x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Phibro Animal Health Corp. is 1.21x versus 7.61x for Boston Scientific Corp.. Usually stocks with elevated PS ratios are considered overvalued.

Masimo Corp. has a net margin of 7.29% compared to Phibro Animal Health Corp.'s net margin of 14.46%. Phibro Animal Health Corp.'s return on equity of 24.77% beat Masimo Corp.'s return on equity of -19.18%.

Phibro Animal Health Corp. has a consensus price target of $43.00, signalling upside risk potential of 3.89%. On the other hand Masimo Corp. has an analysts' consensus of $183.13 which suggests that it could grow by 32.61%. Given that Masimo Corp. has higher upside potential than Phibro Animal Health Corp., analysts believe Masimo Corp. is more attractive than Phibro Animal Health Corp..

Phibro Animal Health Corp. has a beta of 0.771, which suggesting that the stock is 22.868% less volatile than S&P 500. In comparison Masimo Corp. has a beta of 1.262, suggesting its more volatile than the S&P 500 by 26.208%.

Phibro Animal Health Corp. has a quarterly dividend of $0.12 per share corresponding to a yield of 1.16%. Masimo Corp. offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Phibro Animal Health Corp. pays 40.46% of its earnings as a dividend. Masimo Corp. pays out -- of its earnings as a dividend. Phibro Animal Health Corp.'s payout ratio is sufficient to cover dividend payouts with earnings for the foreseeable future.

Phibro Animal Health Corp. quarterly revenues are $363.9M, which are smaller than Masimo Corp. quarterly revenues of $371.5M. Phibro Animal Health Corp.'s net income of $26.5M is lower than Masimo Corp.'s net income of $53.7M. Notably, Phibro Animal Health Corp.'s price-to-earnings ratio is 24.88x while Masimo Corp.'s PE ratio is 116.80x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Phibro Animal Health Corp. is 1.21x versus 4.36x for Masimo Corp.. Usually stocks with elevated PS ratios are considered overvalued.

Envista Holdings Corp. has a net margin of 7.29% compared to Phibro Animal Health Corp.'s net margin of -4.52%. Phibro Animal Health Corp.'s return on equity of 24.77% beat Envista Holdings Corp.'s return on equity of 0.5%.

Phibro Animal Health Corp. has a consensus price target of $43.00, signalling upside risk potential of 3.89%. On the other hand Envista Holdings Corp. has an analysts' consensus of $22.00 which suggests that it could grow by 7.58%. Given that Envista Holdings Corp. has higher upside potential than Phibro Animal Health Corp., analysts believe Envista Holdings Corp. is more attractive than Phibro Animal Health Corp..

Phibro Animal Health Corp. has a beta of 0.771, which suggesting that the stock is 22.868% less volatile than S&P 500. In comparison Envista Holdings Corp. has a beta of 1.025, suggesting its more volatile than the S&P 500 by 2.453%.

Phibro Animal Health Corp. has a quarterly dividend of $0.12 per share corresponding to a yield of 1.16%. Envista Holdings Corp. offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Phibro Animal Health Corp. pays 40.46% of its earnings as a dividend. Envista Holdings Corp. pays out -- of its earnings as a dividend. Phibro Animal Health Corp.'s payout ratio is sufficient to cover dividend payouts with earnings for the foreseeable future.

Phibro Animal Health Corp. quarterly revenues are $363.9M, which are smaller than Envista Holdings Corp. quarterly revenues of $669.9M. Phibro Animal Health Corp.'s net income of $26.5M is higher than Envista Holdings Corp.'s net income of -$30.3M. Notably, Phibro Animal Health Corp.'s price-to-earnings ratio is 24.88x while Envista Holdings Corp.'s PE ratio is 244.62x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Phibro Animal Health Corp. is 1.21x versus 1.33x for Envista Holdings Corp.. Usually stocks with elevated PS ratios are considered overvalued.

GeneDx Holdings Corp. has a net margin of 7.29% compared to Phibro Animal Health Corp.'s net margin of -6.54%. Phibro Animal Health Corp.'s return on equity of 24.77% beat GeneDx Holdings Corp.'s return on equity of 0.82%.

Phibro Animal Health Corp. has a consensus price target of $43.00, signalling upside risk potential of 3.89%. On the other hand GeneDx Holdings Corp. has an analysts' consensus of $160.89 which suggests that it could grow by 0.32%. Given that Phibro Animal Health Corp. has higher upside potential than GeneDx Holdings Corp., analysts believe Phibro Animal Health Corp. is more attractive than GeneDx Holdings Corp..

Phibro Animal Health Corp. has a beta of 0.771, which suggesting that the stock is 22.868% less volatile than S&P 500. In comparison GeneDx Holdings Corp. has a beta of 2.025, suggesting its more volatile than the S&P 500 by 102.538%.

Phibro Animal Health Corp. has a quarterly dividend of $0.12 per share corresponding to a yield of 1.16%. GeneDx Holdings Corp. offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Phibro Animal Health Corp. pays 40.46% of its earnings as a dividend. GeneDx Holdings Corp. pays out -- of its earnings as a dividend. Phibro Animal Health Corp.'s payout ratio is sufficient to cover dividend payouts with earnings for the foreseeable future.

Phibro Animal Health Corp. quarterly revenues are $363.9M, which are larger than GeneDx Holdings Corp. quarterly revenues of $116.7M. Phibro Animal Health Corp.'s net income of $26.5M is higher than GeneDx Holdings Corp.'s net income of -$7.6M. Notably, Phibro Animal Health Corp.'s price-to-earnings ratio is 24.88x while GeneDx Holdings Corp.'s PE ratio is 2,659.62x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Phibro Animal Health Corp. is 1.21x versus 11.44x for GeneDx Holdings Corp.. Usually stocks with elevated PS ratios are considered overvalued.